News archive

/News archive/

Important developments for Emotra

Emotra has reached an important stage in its development. A few days ago, a scientific article was published based on a compilation of the results of earlier blind studies. It shows that hyporeactivity is a clear and strong marker for suicide risk. Furthermore, the Company was recently invited by one of Great Britain’s leading chains [...]

By | October 1st, 2018|INVESTORS|Comments Off on Important developments for Emotra

New publication demonstrates the strength of Emotra’s test, EDOR®

A study conducted by Emotra’s Chief of Research and the inventor of EDOR®, Lars-Håkan Thorell, and the biostatistician Karl Wahlin demonstrates how strongly the company’s test identifies patients at risk of committing suicide.   180904- Emotra - PM - New publication demonstrates the strength of EDOR tests

By | September 4th, 2018|INVESTORS|Comments Off on New publication demonstrates the strength of Emotra’s test, EDOR®

Emotra is granted a patent in Japan

As we have previously announced, Japan is one of Emotra’s high-priority markets. The company has applied for patents in the EU, USA, Canada and Japan. The Japanese patent office has now informed us that Emotra’s Japanese patent application number 2016-516080 has been approved.   180730- Emotra - PM - Patent approved in Japan

By | July 30th, 2018|INVESTORS|Comments Off on Emotra is granted a patent in Japan

Emotra focuses on Europe’s largest cities

As we notified in a previous newsletter and our annual report, Emotra has changed its market introduction strategy for EDOR®. In the first and second quarter of 2018, we have been working the markets more directly and with a greater geographical focus. Given the company’s resources and previous experience, we have chosen to focus our [...]

By | July 5th, 2018|INVESTORS|Comments Off on Emotra focuses on Europe’s largest cities

Emotra: Agreement with research group on compensation for clinical tests

Emotra AB (“Emotra”) hereby announces that an agreement has been reached with a group of researchers at the faculty of medicine at the University of Warsaw. The agreement concerns financial compensation for EDOR® tests in a clinical study. The study in question is a continuation of a research project that was started in connection with [...]

By | May 7th, 2018|INVESTORS|Comments Off on Emotra: Agreement with research group on compensation for clinical tests

Documents for the Annual General Meeting now available

Emotra AB (publ) (“Emotra”) today announces that the Company’s Annual Report for the financial year 2017, as well as other documents required for the Annual General Meeting are available from the Company’s web site (www.emotra.se) as of today, and are also provided upon request by the Company (see address below). 180418 - Emotra- PM - [...]

By | April 18th, 2018|INVESTORS|Comments Off on Documents for the Annual General Meeting now available